New lung Drug's safety check: how does it mix with existing meds?

NCT ID NCT07229716

Recruiting now Knowledge-focused Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called HRS-9813 in 20 healthy volunteers to see how it interacts with two standard treatments for pulmonary fibrosis (lung scarring): pirfenidone and nintedanib. The goal is to measure drug levels in the blood and check for side effects. This study does not treat the disease but provides important safety and dosing information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-9813, pirfenidone, nintedanib
What this could lead to: If successful, this could help determine safe dosing when HRS-9813 is combined with existing pulmonary fibrosis treatments.
What could go wrong: This is an early Phase 1 study in healthy people, not patients. It only measures drug levels and safety, not whether the combination works for the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY FIBROSIS

Contacts and locations

Locations

Tangdu Hospital, Fourth Military Medical University
RECRUITING

Xi’an, Shanxi, 710026, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.